BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
51 hedge funds and large institutions have $17.2M invested in BRAINSTORM CELL THERAPUTC in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 1 reducing their positions, and 6 closing their positions.
2,000% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 1
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
94% more capital invested
Capital invested by funds: $8.85M → $17.2M (+$8.36M)
19% more funds holding
Funds holding: 43 → 51 (+8)
9% more call options, than puts
Call options by funds: $3.72M | Put options by funds: $3.41M
0.29% more ownership
Funds ownership: 0.61% → 0.9% (+0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.31M |
| 2 |
Renaissance Technologies
New York
|
+$1.26M |
| 3 |
BlackRock
New York
|
+$1.14M |
| 4 |
Millennium Management
New York
|
+$1.03M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$676K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$340K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$234K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
-$88K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$63.7K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$50K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$340K | -4,354 | Closed |
|
|
52
Group One Trading
Chicago,
Illinois
| – | -$234K | -3,004 | Closed |
|
|
53
Wolverine Trading
Chicago,
Illinois
| – | -$88K | -1,370 | Closed |
|
|
54
Citadel Advisors
Miami,
Florida
| – | -$63.7K | -816 | Closed |
|
|
55
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$50K | -791 | Closed |
|
56
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$15K | -235 | Closed |
|
BCLI Hedge Fund Activity: Q1 2020 in Review
51 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2020, worth a combined $17.2M — up 94% from $8.85M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BCLI positions and 6 closed out — a net gain of 10 holders — while 21 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.31M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $340K sold.
- 51 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2020, up from 43 in Q4 2019.
- Funds reported $17.2M of BRAINSTORM CELL THERAPUTC stock for Q1 2020, up 94% quarter-over-quarter.
- 16 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2020 and 6 closed out, a net change of +10 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2020 was Vanguard Group, an estimated $2.31M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2020 was Susquehanna International Group, an estimated $340K sold.
Based on aggregated 13F filings for Q1 2020.